Skip to content

Mometasone Furoate

FDA-approved product (ointment, topical), marketed as Asmanex Hfa, Asmanex Twisthaler, Elocon and 4 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Mometasone Furoate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Airway obstruction
  • Allergic rhinitis
  • Asthma
  • Nasal Cavity Polyp
  • Nasal congestion
  • Nasal polyposis
  • Seasonal allergic rhinitis
  • Skin disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids, potent (group iii); Corticosteroids, potent, other combinations; Corticosteroids; Glucocorticoids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis36.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Mometasone Furoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED)

    NCT00381485 · start 2006-07-01

    Registered record
    Registry ID
    NCT00381485
    Conditions
    Asthma
    Interventions
    Mometasone furoate/formoterol (MF/F) combination; Mometasone furoate/formoterol (MF/F) combination; Mometasone furoate MDI (MF MDI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-07-01
    Completion
    2008-01-01
    Enrolment
    834

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionMometasone furoate/formoterol (MF/F) combination; Mometasone furoate/formoterol (MF/F) combination; Mometasone furoate MDI (MF MDI)
    PhasePhase 3
    Registry statusCompleted
  • Mometasone Furoate on Sleep Disturbances in Subjects With Seasonal Allergic Rhinitis (Study P04608) (COMPLETED)

    NCT00358527 · start 2006-05

    Registered record
    Registry ID
    NCT00358527
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    Mometasone Furoate Nasal Spray (MFNS); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-05
    Completion
    2006-11
    Enrolment
    401

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    InterventionMometasone Furoate Nasal Spray (MFNS); Placebo
    PhasePhase 4
    Registry statusCompleted
  • Placebo-controlled Trial With Nasonex for Nasal Obstruction Secondary to Adenoids Hypertrophy in Children (P04367)(TERMINATED)

    NCT00553891 · start 2006-05

    Registered record
    Registry ID
    NCT00553891
    Conditions
    Nasal Obstruction; Adenoids Hypertrophy; Adenoidectomy
    Interventions
    mometasone furoate nasal spray; placebo nasal spray
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2006-05
    Completion
    2009-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNasal Obstruction; Adenoids Hypertrophy; Adenoidectomy
    Interventionmometasone furoate nasal spray; placebo nasal spray
    PhasePhase 4
    Registry statusWithdrawn
  • A Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis (Study P03748)(COMPLETED)

    NCT00779545 · start 2004-04-08

    Registered record
    Registry ID
    NCT00779545
    Conditions
    Rhinitis, Allergic, Perennial
    Interventions
    Placebo; Mometasone furoate; Mometasone furoate; Mometasone furoate; Mometasone furoate; Mometasone furoate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-04-08
    Completion
    2004-08-06
    Enrolment
    455

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial
    InterventionPlacebo; Mometasone furoate; Mometasone furoate; Mometasone furoate +2 more
    PhasePhase 2
    Registry statusCompleted
  • Mometasone Furoate Nasal Spray for Treatment of Nasal Polyposis After Surgery (Study P03218)

    NCT00731185 · start 2003-09-01

    Registered record
    Registry ID
    NCT00731185
    Conditions
    Nasal Polyps
    Interventions
    Mometasone Furoate Nasal Spray; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-09-01
    Completion
    2005-09-01
    Enrolment
    162

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNasal Polyps
    InterventionMometasone Furoate Nasal Spray; Placebo
    PhasePhase 3
    Registry statusCompleted